EU funding for Abera in VacPath consortium

Abera and partners from The Netherlands, Germany, Switzerland, Denmark and Italy receive more than 2.5 MEUR of funding from the EU for the project Novel vaccine vectors resist pathogen challenge – VacPath. VacPath is a Horizon 2020 MSCA-funded Innovative Training Network that aims to develop novel vector-based vaccines eliciting mucosal immunity against the intracellular bacterium Chlamydia trachomatis.

For more detailed descriptions of the project, please click below: